Literature DB >> 25753044

Genetically engineered lymphocytes and adoptive cell therapy: cancer immunotherapy's smart bombs.

S K Libutti1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25753044     DOI： 10.1038/cgt.2015.1

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN： 0929-1903            Impact factor:   5.987


× No keyword cloud information.
  10 in total

1.  Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells.

Authors:  Keisuke Watanabe; Seitaro Terakura; Anton C Martens; Tom van Meerten; Susumu Uchiyama; Misa Imai; Reona Sakemura; Tatsunori Goto; Ryo Hanajiri; Nobuhiko Imahashi; Kazuyuki Shimada; Akihiro Tomita; Hitoshi Kiyoi; Tetsuya Nishida; Tomoki Naoe; Makoto Murata
Journal:  J Immunol       Date:  2014-12-17       Impact factor: 5.422

2.  Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells.

Authors:  Yao Wang; Wen-ying Zhang; Qing-wang Han; Yang Liu; Han-ren Dai; Ye-lei Guo; Jian Bo; Hui Fan; Yan Zhang; Ya-jing Zhang; Mei-xia Chen; Kai-chao Feng; Quan-shun Wang; Xiao-bing Fu; Wei-dong Han
Journal:  Clin Immunol       Date:  2014-10-16       Impact factor: 3.969

Review 3.  Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer.

Authors:  Michael S Magee; Adam E Snook
Journal:  Discov Med       Date:  2014-11       Impact factor: 2.970

4.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

5.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

Authors:  Julie R Brahmer; Scott S Tykodi; Laura Q M Chow; Wen-Jen Hwu; Suzanne L Topalian; Patrick Hwu; Charles G Drake; Luis H Camacho; John Kauh; Kunle Odunsi; Henry C Pitot; Omid Hamid; Shailender Bhatia; Renato Martins; Keith Eaton; Shuming Chen; Theresa M Salay; Suresh Alaparthy; Joseph F Grosso; Alan J Korman; Susan M Parker; Shruti Agrawal; Stacie M Goldberg; Drew M Pardoll; Ashok Gupta; Jon M Wigginton
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

Review 6.  Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies.

Authors:  Saar Gill; Carl H June
Journal:  Immunol Rev       Date:  2015-01       Impact factor: 12.988

7.  Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma.

Authors:  Sofia Lyford-Pike; Shiwen Peng; Geoffrey D Young; Janis M Taube; William H Westra; Belinda Akpeng; Tullia C Bruno; Jeremy D Richmon; Hao Wang; Justin A Bishop; Lieping Chen; Charles G Drake; Suzanne L Topalian; Drew M Pardoll; Sara I Pai
Journal:  Cancer Res       Date:  2013-01-03       Impact factor: 12.701

8.  Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

Authors:  Suzanne L Topalian; Mario Sznol; David F McDermott; Harriet M Kluger; Richard D Carvajal; William H Sharfman; Julie R Brahmer; Donald P Lawrence; Michael B Atkins; John D Powderly; Philip D Leming; Evan J Lipson; Igor Puzanov; David C Smith; Janis M Taube; Jon M Wigginton; Georgia D Kollia; Ashok Gupta; Drew M Pardoll; Jeffrey A Sosman; F Stephen Hodi
Journal:  J Clin Oncol       Date:  2014-03-03       Impact factor: 44.544

9.  Finding suitable targets is the major obstacle to cancer gene therapy.

Authors:  Steven A Rosenberg
Journal:  Cancer Gene Ther       Date:  2014-02       Impact factor: 5.987

Review 10.  Adoptive immunotherapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors.

Authors:  Hiroshi Fujiwara
Journal:  Pharmaceuticals (Basel)       Date:  2014-12-15
  10 in total
  3 in total

Review 1.  Is metastatic pancreatic cancer an untargetable malignancy?

Authors:  Hampig Raphael Kourie; Joseph Gharios; Fadi Elkarak; Joelle Antoun; Marwan Ghosn
Journal:  World J Gastrointest Oncol       Date:  2016-03-15

2.  Down regulation of G protein-coupled receptor 137 expression inhibits proliferation and promotes apoptosis in leukemia cells.

Authors:  Li-Jie Men; Ji-Zhu Liu; Hai-Ying Chen; Li Zhang; Shuang-Feng Chen; Tai-Wu Xiao; Jing-Xia Wang; Guang-Yao Li; Ya-Ping Wu
Journal:  Cancer Cell Int       Date:  2018-01-29       Impact factor: 5.722

Review 3.  Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes.

Authors:  Andrew L Sochacki; Melissa A Fischer; Michael R Savona
Journal:  Onco Targets Ther       Date:  2016-04-15       Impact factor: 4.147
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.